These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 11288542)

  • 1. [Bone metastasis. Can a new bisphosphonate offer control?].
    MMW Fortschr Med; 2001 Mar; 143(9):59. PubMed ID: 11288542
    [No Abstract]   [Full Text] [Related]  

  • 2. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bisphosphonates in bone metastases. Fewer fractures, less pain].
    MMW Fortschr Med; 2002 Sep; 144(39):53. PubMed ID: 12422697
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
    Boikos SA; Hammers HJ
    J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
    [No Abstract]   [Full Text] [Related]  

  • 5. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
    Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which bisphosphonate to treat bone metastases?
    Costa L
    Lancet Oncol; 2014 Jan; 15(1):15-6. PubMed ID: 24332513
    [No Abstract]   [Full Text] [Related]  

  • 8. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
    Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
    Leite AF; Figueiredo PT; Melo NS; Acevedo AC; Cavalcanti MG; Paula LM; Paula AP; Guerra EN
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul; 102(1):14-21. PubMed ID: 16831667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 12. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
    Serefoglu EC; Balbay MD
    Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative bisphosphonate targets and mechanisms of action.
    Bukowski JF; Dascher CC; Das H
    Biochem Biophys Res Commun; 2005 Mar; 328(3):746-50. PubMed ID: 15694409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of effective bisphosphonate therapy for bone metastasis from breast cancer with multiorganic metastases].
    Sueyoshi K; Ogura Y; Komori T; Takahashi M; Tian TX; Tatsumi T; Matsuki M; Saika Y; Uesugi Y; Utsunomiya K; Inomata Y; Narabayashi I
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1795-9. PubMed ID: 12402432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the horizon: can bisphosphonates prevent bone metastases?
    Coleman R
    Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of bisphosphonate use for the dentist: an introduction.
    Kurtzman GM; Silverstein LH; Peden J; Shatz PC
    Dent Today; 2006 Jun; 25(6):80, 82-5; quiz 85. PubMed ID: 16792113
    [No Abstract]   [Full Text] [Related]  

  • 19. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.